Cargando…
SIRT2 inhibitor SirReal2 enhances anti‐tumor effects of PI3K/mTOR inhibitor VS‐5584 on acute myeloid leukemia cells
BACKGROUND: Acute myeloid leukemia (AML) is a highly aggressive form of cancer that is frequently diagnosed in adults and small molecule inhibitors have gained significant attention as a potential treatment option for AML. METHODS: The up‐regulated genes in AML were identified through bioinformatics...
Autores principales: | Luo, Yiming, Zhao, Haijun, Zhu, Jingtao, Zhang, Liyi, Zha, Jie, Zhang, Li, Ding, Yi, Jian, Xinyi, Xia, Junjie, Xu, Bing, Qi, Zhongquan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557894/ https://www.ncbi.nlm.nih.gov/pubmed/37658623 http://dx.doi.org/10.1002/cam4.6480 |
Ejemplares similares
-
VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
por: Shao, Zheren, et al.
Publicado: (2015) -
BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K/mTOR dual inhibitor VS-5584
por: Xu, Ming, et al.
Publicado: (2020) -
HaloTag‐Targeted Sirtuin‐Rearranging Ligand (SirReal) for the Development of Proteolysis‐Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)
por: Schiedel, Matthias, et al.
Publicado: (2020) -
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer
por: Ning, Changwen, et al.
Publicado: (2017) -
Validation of the Slow Off‐Kinetics of Sirtuin‐Rearranging Ligands (SirReals) by Means of Label‐Free Electrically Switchable Nanolever Technology
por: Schiedel, Matthias, et al.
Publicado: (2020)